Anti-Proliferative and Pro-Apoptotic Activities of Synthesized 3,4,5 Tri-Methoxy Ciprofloxacin Chalcone Hybrid, Through P53 Up-Regulation in HepG2 and MCF7 Cell Lines

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2021 Oct 29

PMID 34711017

Citations 11

Authors

Marwa A Eisa

Moustafa Fathy

Gamal El-Din A A Abuo-Rahma

Mohamed Abdel-Aziz

Maiiada Hassan Nazmy

Affiliations

Soon will be listed here.

Abstract

Background: Cancer is a significant health problem around the world and one of the leading causes of human death. The need for novel, selective and non-toxic anti-cancer agents is still urging.

Aim Of The Work: to investigate the anti-proliferative and pro-apoptotic effects of the synthesized ciprofloxacin 3,4,5 tri-methoxy chalcone hybrid (CCH) on the HepG2 hepatocellular carcinoma and MCF7 breast carcinoma cell lines.

Materials And Methods: HepG2 and MCF7cell lines were treated with CCH. Cell viability and cell cycle analysis were performed. Protein and mRNA expression levels of P53, COX-2 and TNF-α were analyzed by western blotting and RT-PCR respectively.

Results: CCH caused concentration and time-dependent reduction in the viability of human HepG2 and MCF7 cells, pre-G1 apoptosis and cell cycle arrest at G2/M stage, significantly higher P53 and TNF-α mRNA and protein expression levels but significantly lower COX2 mRNA and protein expression levels.

Conclusion: CCH showed obvious anti-proliferative and apoptosis-inducing activities in both cell lines.

Citing Articles

Ciprofloxacin-encapsulated solid lipid nanoparticles: a comprehensive biochemical analysis of cytotoxic effects, proliferation inhibition, and apoptotic induction in KG1-a leukemia cells.

Kadhim S, Dehghan G, Mahdavi M Med Oncol. 2025; 42(3):75.

PMID: 39945900 DOI: 10.1007/s12032-025-02619-2.

From Infection to Tumor: Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents.

Hassan H, Hassan R, Elmagzoub R, Al-Emam A, Kossenas K, Abdel-Samea A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861135 PMC: 11768150. DOI: 10.3390/ph18010072.

From Microcirculation to Aging-Related Diseases: A Focus on Endothelial SIRT1.

Law M, Wang P, Zhou Z, Wang Y Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598406 PMC: 11597311. DOI: 10.3390/ph17111495.

Design, synthesis and evaluation of novel norfloxacin analogs as potent anticancer and antioxidant agents.

Qurban F, Shahzad S, Khaskheli M, Khan S, Khan S, Rauf W Future Med Chem. 2024; 16(17):1777-1789.

PMID: 39115052 PMC: 11457674. DOI: 10.1080/17568919.2024.2383165.

Ciprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents.

Peter S, Aderibigbe B Curr Top Med Chem. 2024; 24(7):644-665.

PMID: 38357952 DOI: 10.2174/0115680266288319240206052223.

References

Muenchen H, Lin D, Walsh M, Keller E, Pienta K . Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res. 2000; 6(5):1969-77. View

Duarte M, de Moraes E, Pontes E, Schluckebier L, de Moraes J, Hainaut P . Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. Cancer Lett. 2009; 279(1):57-64. DOI: 10.1016/j.canlet.2009.01.021. View

Moran A, Ortega P, De Juan C, Fernandez-Marcelo T, Frias C, Sanchez-Pernaute A . Differential colorectal carcinogenesis: Molecular basis and clinical relevance. World J Gastrointest Oncol. 2010; 2(3):151-8. PMC: 2999176. DOI: 10.4251/wjgo.v2.i3.151. View

Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn E, Schuppan D . Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002; 86(3):443-8. PMC: 2375221. DOI: 10.1038/sj.bjc.6600079. View

Naseem M, Othman E, Fathy M, Iqbal J, Howari F, AlRemeithi F . Integrated structural and functional analysis of the protective effects of kinetin against oxidative stress in mammalian cellular systems. Sci Rep. 2020; 10(1):13330. PMC: 7414151. DOI: 10.1038/s41598-020-70253-1. View

Beberok A, Wrzesniok D, Minecka A, Rok J, Delijewski M, Rzepka Z . Ciprofloxacin-mediated induction of S-phase cell cycle arrest and apoptosis in COLO829 melanoma cells. Pharmacol Rep. 2018; 70(1):6-13. DOI: 10.1016/j.pharep.2017.07.007. View

Nagura S, Otaka S, Koike C, Okabe M, Yoshida T, Fathy M . Effect of exogenous Oct4 overexpression on cardiomyocyte differentiation of human amniotic mesenchymal cells. Cell Reprogram. 2013; 15(5):471-80. DOI: 10.1089/cell.2013.0002. View

Dai J, Huang Y, He A . Dihydromethysticin kavalactone induces apoptosis in osteosarcoma cells through modulation of PI3K/Akt pathway, disruption of mitochondrial membrane potential and inducing cell cycle arrest. Int J Clin Exp Pathol. 2015; 8(5):4356-66. PMC: 4502999. View

Fathy M, Nikaido T . In vivo modulation of iNOS pathway in hepatocellular carcinoma by Nigella sativa. Environ Health Prev Med. 2013; 18(5):377-85. PMC: 3773091. DOI: 10.1007/s12199-013-0336-8. View

10.

Alaaeldin R, Abuo-Rahma G, Zhao Q, Fathy M . Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-β/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells. Anticancer Res. 2021; 41(5):2383-2395. DOI: 10.21873/anticanres.15013. View

11.

Paul M, Gafter-Gvili A, Fraser A, Leibovici L . The anti-cancer effects of quinolone antibiotics?. Eur J Clin Microbiol Infect Dis. 2007; 26(11):825-31. DOI: 10.1007/s10096-007-0375-4. View

12.

Eldafashi N, Darlay R, Shukla R, McCain M, Watson R, Liu Y . A Role in the Genetic Predisposition to NAFLD-HCC?. Cancers (Basel). 2021; 13(6). PMC: 8003582. DOI: 10.3390/cancers13061412. View

13.

Fathy M, Awale S, Nikaido T . Phosphorylated Akt Protein at Ser473 Enables HeLa Cells to Tolerate Nutrient-Deprived Conditions. Asian Pac J Cancer Prev. 2017; 18(12):3255-3260. PMC: 5980880. DOI: 10.22034/APJCP.2017.18.12.3255. View

14.

Reuveni D, Halperin D, Shalit I, Priel E, Fabian I . Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010; 37(2):463-71. DOI: 10.3892/ijo_00000695. View

15.

Vane J, Bakhle Y, Botting R . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97-120. DOI: 10.1146/annurev.pharmtox.38.1.97. View

16.

de Moraes E, Dar N, De Moura Gallo C, Hainaut P . Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer. 2007; 121(5):929-37. DOI: 10.1002/ijc.22899. View

17.

Fathy M, Nikaido T . In vivo attenuation of angiogenesis in hepatocellular carcinoma by Nigella sativa. Turk J Med Sci. 2018; 48(1):178-186. DOI: 10.3906/sag-1701-86. View

18.

Abdel-Aziz M, Park S, Abuo-Rahma G, Sayed M, Kwon Y . Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity. Eur J Med Chem. 2013; 69:427-38. DOI: 10.1016/j.ejmech.2013.08.040. View

19.

Aranha O, Wood Jr D, Sarkar F . Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000; 6(3):891-900. View

20.

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso M . Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014; 2014:149185. PMC: 4036716. DOI: 10.1155/2014/149185. View